Special Issue: Updates on the COVID 19 waves

Click here for the PAST COVID-19 emerging and re-emerging waves Virtual conference IN 2021

Background

COVID-19 came with Norvel surprises and consequently claiming many victims.  Lockdown came and other measures to slow down the tenacity of the diseases. The world waited for the vaccine and finally, the vaccine came and many people have already been vaccinated while others are on their way to be vaccinated. However, the infection rate and case fatality continue to rise especially with mutant strains entering the picture. This makes one fact very clear that we are far from completely understanding the dynamics of COVID 19 transmission, and management. What can we do with the second, third, and imminent fourth and many more waves coming on board in different Regions of the world?

Invitation of research papers

Special Journal of Public Health, Nutrition and Dietetics hereby invites original previously unpublished research papers that will help us to elucidate the following points and questions being asked by various stakeholders including the infectious diseases society of America IDSA. All forms of papers are accepted from Reviews, (Full, systematic, and mini) meta-analysis, Short communication, Opinion papers, position papers, short communication, and letters to the Editor in any of the following thematic points.

1. SARS-CoV-2 and COVID 19 respiratory transmission in the healthcare setting
2. Staging of the respiratory protection levels of medical procedures in emerging and reemerging waves of the COVID-19
3. Safety of strategies currently used to prevent infection in the Healthcare Personnel during emergency and disaster settings in which recommendations for use of personal protective equipment’s [PPE] in conventional settings cannot be obeyed
4. Researches that compare the performance of the different assays in adult and pediatric populations; specimen types, and collection,
5. Test performance variation as a function of specimen type and time from symptom onset
6. Role of steroids and other anti-inflammatory agents, Immuno-therapeutics, anticoagulation, and antiplatelet therapy
7. Post-exposure prophylaxis, Drug safety, clinical disparities evaluation, antibiotics secondary bacterial infections,
8. Appropriateness of antibiotic use for COVID-19 patients and impact of antibiotic use on COVID-19 patients
9. Antimicrobial resistance; antimicrobial stewardship and secondary infections
10. Zoonotic transmission – Viral evolution – Transmission dynamics & contact tracing – Prospective cohort studies
11. Follow-up studies to see long-term impacts in patients who survive. Whether immune parameters change? Other?
12. what are the dynamics of the antibody response over time? Can we estimate time since infection from antibody response? Are there unanticipated long-term outcomes
13. Correlates of disease progression, identifying epidemiologic risk factors for increased adverse outcomes and Cross-sectional seroprevalence
14. what is the age-specific and spatial distributions of prior exposure? – Household contact studies
15. what baseline serological responses correlate with protection? What are the risk factors for symptomatic infection?
16. identifying potential correlates of protection in children: Risks of vertical transmission of SARS-CoV2;
17. Risk factors for severe disease and How do the risk profile differ depending on age?
18. Studies on seroconversion and which antibodies confer immunity
19. Pathogenesis of lung/ cardiac damage and whether therapeutics targeting damage would be beneficial, viral co-infections and Biobanking of samples
20. How the lung microbiome modulates the response to COVID-19

Submission

All papers intended for this call are summited here and indicated Special issues on COVID 19 waves to enable the Board of Editors to pay special and expedited attention it deserves

Date

The duration of this special edition is six months in the first instance from May to December 2022. 

Coordinating Editors

Dr Ezeonwumelu JOC

Ezeonwumelu JOC – [Ph.D. in clinical and Bio pharmacy from Mbarara University of Science and Technology (MUST) and M. Pharm, and B. Pharm from the University of Lagos Nigeria, Masters in Public Health from Bishop Stuart University, Uganda, BSc in Biochemistry from the University of Lagos], is a Public Health Pharmacist, lecturer, HOD, and former Dean, Sch of Pharmacy, KIU Uganda. He is skilled in Clinical/pharmaceutical care, Toxicology, & phytochemistry analysis], Pharmaceutical Microbiology, and pharmacotherapy. His expertise in the therapy of tropical disease with medicinal herbs is an asset

Dr Joseph F Hokello

Dr. Joseph Francis Hokello [Ph.D.] is a molecular virologist and Microbial epidemiologist. Dr. Hokello holds a Ph.D. in molecular virology from Case Western Reserve University, the USA, and an MSc in molecular biology and biotech from Makerere University. Currently, Dr. Hokello is a senior lecturer at KIU, Western Campus in Uganda.  His current research interests include investigating the individual role of AP-1 and NFAT transcription factors in the reactivation of HIV latency in resting memory T cells obtained from patients on prolonged Highly Active Antiretroviral therapy HAART

Submission Guideline

All papers should be written according to instructions to authors found here... All paper types are accepted under this call.

All papers must be submitted through our online article management system for quick attention. Please click here to submit…

Deadline for the call

This call will end on December 30th, 2022

The cost for publication is 80% OFF

All nonfunded ACCEPTED papers submitted under this call will receive an 80% waiver as outlined on our page for waiver terms and conditions depending on the country of affiliation of the researchers seen here….Article-processing charges are only payable after papers are accepted and there is no fee for rejected papers.

To be more specific, Low-income countries will pay US$44 dollars, Middle-income countries will pay US$84 dollars, while High-income countries will pay US$124 dollars respectively.